INTRODUCTION {#s1}
============

Endometrial cancer (EC) is the most common gynecologic cancer and the sixth most deathly cancer in women from western countries \[[@R1]\]. Myometrial invasion is one of the most important prognostic factors of EC and represents an increase in the rate of recurrence and a decrease in the 5-year survival \[[@R2]\]. The first step of myometrial invasion is characterized by the dissociation of tumor cells from the epithelial layer of the endometrial glands, and their subsequent infiltration through the basement membrane into the adjacent layer, the myometrium \[[@R3]\]. For that to happen, several authors suggest that epithelial tumor cells need to undergo an epithelial-to-mesenchymal transition (EMT). Moreover, it is known that in invading tumors this process takes place at the invasive front \[[@R4]--[@R6]\]. EMT is a dynamic process controlled by external signals coming from the tumor cells microenvironment, that involves cellular loss of polarity, loosen cell-cell contacts, reorganization of cytoskeleton and acquisition of plasticity, motility and invasive capabilities. Multiple factors have been described as being responsible for producing EMT in EC, such as ETV5, estrogen and progesterone receptors, and TGF-β, among others \[[@R3]\].

Activated-leukocyte cell adhesion molecule (ALCAM) is a cell-cell adhesion molecule of 105-kDa from the immunoglobulin superfamily (IgSF) that participates either in homotypic (ALCAM-ALCAM) or heterotypic (ALCAM-CD6) interactions between adjacent cells \[[@R7]\]. ALCAM presents 5 extracellular immunoglobulin domains (D1--D5), comprising 2 NH2-terminal, membrane-distal variable-(V)-type and 3 membrane-proximal constant-(C2)-type Ig folds, a transmembrane-region and a short carboxy-terminal cytoplasmic tail. The extracellular domains provide two structural and functional modules, responsible for ligand affinity (D1-D2) that mediates receptor *trans-trans*-interactions between opposing cells, and avidity (D3-D5). The strength of the avidity is controlled by recruitment of ALCAM molecules to the site of cell-cell contact and by receptor *cis*-oligomerization via the C-type immunoglobulin domains. Coordination of both modules is necessary for stable ALCAM-ALCAM interaction, leading to the formation of a tight bilayered ALCAM network \[[@R8]\]. Both, homotypic and heterotypic interactions are mediated through its amino-terminal V domain (D1). ALCAM-ALCAM interactions are described as a D1--D1 interaction, while in ALCAM--CD6 interactions the ALCAM D1 domain binds to the CD6 membrane-proximal scavenger receptor cysteine rich (SRCR) domain \[[@R9], [@R10]\].

Activation of ALCAM-mediated adhesion is dynamically regulated through actin cytoskeleton-dependent clustering. Zimmerman et al. described the interaction between ALCAM and the actin cytoskeleton \[[@R11]\]. This interaction could be allowed by the presence in its short cytoplasmic tail of a positive-charge-rich domain (PCRD) as well as a PDZ-binding motif KTEA placed at the C-terminus \[[@R12]\]. The inhibition of actin polymerization by low levels of cytochalasin D stimulates homotypic ALCAM--ALCAM interactions, increases protein lateral mobility, and the formation of ALCAM clusters in the cell surface, demonstrating that cytoskeleton regulates ALCAM-mediated adhesion \[[@R13]\]. Moreover, ALCAM has been observed to form a supra-molecular complex with Syntenin-1 and Ezrin \[[@R14]\]. PKCα also plays a role in the cytoskeleton-dependent avidity modulation of ALCAM and regulates the supra-molecular complex formed by ALCAM-Ezrin \[[@R15]\].

ALCAM expression in the cell surface can be regulated by endocytosis or protein cleavage. In fact, ALCAM co-localizes with clathrin in a process that is regulated by ubiquitination and dependent on ERK phosphorylation \[[@R16], [@R17]\]. ALCAM levels can be also regulated by protein shedding via ADAM-17 metalloproteinase \[[@R18]\], generating a soluble 96-kDa form and a truncated membrane-bound. ALCAM is widely distributed within tissues and its function has been reported in extensive biological processes \[[@R19]\]. In the last years, it has been associated to the tumorigenesis of many cancers \[[@R20]--[@R27]\]. However, ALCAM expression and localization within the tumor cell have generated great controversy, and its relation to prognosis remain still unclear \[[@R28]\]. In addition, ALCAM shedding has been reported in the serum of breast, ovarian, thyroid and pancreatic cancer patients and in all the cases, related to poor clinical outcome \[[@R24], [@R29]--[@R31]\]. We have previously demonstrated that ALCAM is an important player in endometrioid endometrial cancer (EEC) dissemination \[[@R32]\]. In fact, we described that ALCAM-positivity is a marker of recurrence in early stage EEC and promotes migration and invasion *in vitro* and *in vivo*.

In this study, we go further in our understanding of ALCAM in EC tumorigenesis by evaluating its full-form expression in two different areas of the tumor and its relation with key molecules associated to the epithelial and mesenchymal context. Immunohistochemical staining for ALCAM in tissues was conducted with an antibody directed against the extracellular domain of the protein. Since, ALCAM can be proteolytically processed by metalloproteinases, thereby generating a soluble ALCAM component and a truncated membrane-bound ALCAM containing the transmembrane and cytoplasmic domain, the antibody recognized the non-cleaved protein.

We found a switch in the functional mode of ALCAM in EEC. Whereas at the superficial area of the tumor ALCAM correlated with the E-Cadherin/β-Catenin adhesion complex, at the invasive front ALCAM could be shed by MMP-9 in poor prognosis scenarios. Moreover, we evaluated the shed ALCAM, or soluble form (sALCAM), in uterine aspirates as a potential diagnostic tool to predict myometrial invasion.

RESULTS {#s2}
=======

ALCAM expression presented a different correlation profile depending on its localization within the tumor {#s2_1}
---------------------------------------------------------------------------------------------------------

We studied the immunohistochemical expression of ALCAM extracellular domain (non-cleaved protein) and a representative set of epithelial (E-cadherin/β-catenin major adhesion complex) and mesenchymal molecules involved in EEC dissemination (ETV5, COX-2, SNAIL, SLUG, MMP-2 and -9), in both the superficial and the invasive areas of the tumor. As our previous results indicated a different behavior of ALCAM regarding tumor differentiation, analyses were performed in the entire population, and in the well-differentiated (GI) and poorly-differentiated (GII-III) subcohorts \[[@R32]\].

Univariate regression analyses were performed as a first approach to evaluate the association between ALCAM and epithelial and mesenchymal markers. Variables that significantly correlated with ALCAM ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) were included in multivariate linear regression models. ALCAM presented a significant positive correlation with the major adhesion complex at the superficial area of the tumor. Whilst β-catenin was retained as an outcome variable in all patients and in the well-differentiated cohort (R=0.437 and 0.394, respectively), E-cadherin was retained in the moderately-poorly differentiated tumors (R=0.445) ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}, Figure [1A](#F1){ref-type="fig"}). By contrast, at the invasive front of the tumor, SNAIL, COX-2 and MMP-9 were retained as outcome variables of the model, in all patients. COX-2 and SNAIL were positively correlated with ALCAM, whilst MMP-9 was negatively correlated. The best regression adjustment was reached in the moderately-poorly differentiated subcohort of patients, in which the model retained ETV5 and MMP-9 (R=0.559). Both molecules showed a negative correlation with ALCAM. Altogether, the results suggested a different functional profile of ALCAM according to its tumor localization, i.e. whilst it correlated with epithelial markers at the superficial tumor, correlations with mesenchymal markers were observed at the invasive front.

![ALCAM expression presented a different correlation profile depending on its localization within the tumor and its decrease at the invasive front is a marker of myometrial invasion\
**(A)** Upper: Full-length ALCAM was significantly and positively correlated with the E-cadherin/β-catenin complex at the superficial tumor and is mainly localized at the cell membrane. Down: At the invasive front, full-length ALCAM is significantly inversely correlated with MMP-9 and ETV5, in the moderately-poorly differentiated EEC. **(B)** ALCAM-negativity, at the invasive front, is a marker of myometrial invasion **(C)** At the invasive front, ALCAM-negative tumors increased from a 21.8% in patients without myometrial invasion to a 45.1% in patients presenting myometrial infiltration (p-value= 0.014).](oncotarget-09-16648-g001){#F1}

ALCAM-negativity at the invasive front of the tumor is a marker of myometrial invasion {#s2_2}
--------------------------------------------------------------------------------------

We further investigated the role of ALCAM at the different tumor areas. At the superficial area, ALCAM expression was unrelated to the clinical parameters of myometrial invasion, tumor grade, and tumor progression. However, it acted as a marker of tumor progression and invasion when analyzed at the invasive front. In this tumor area, ALCAM significantly decreased along tumor stages and in tumors with myometrial invasion \>50% (Table [1](#T1){ref-type="table"}, Figure [1B-1C](#F1){ref-type="fig"}). In fact, the potential of ALCAM-negativity as an independent prognostic factor of myometrial invasion was confirmed by multivariate logistic regression analysis with an OR 3.273, together with the tumor grade (OR 3.484) (Table [2](#T2){ref-type="table"}).

###### ALCAM and clinical parameters

  Variable, No. (%)                   Σ     ALCAM Positive^\*^   ALCAM Negative^†^   P-value
  ----------------------------------- ----- -------------------- ------------------- -------------
  **Superficial area of the tumor**                                                  
  **FIGO**                            116   82 (70.7)            34 (29.3)           0.208
   IA                                 56    42 (75.0)            14 (25.0)           
   IB                                 41    28 (68.3)            13 (31.7)           
   II                                 15    11 (73.3)            4 (26.7)            
   III                                4     1 (25.0)             3 (75.0)            
  **Grade**                           116   82 (70.7)            34 (29.3)           0.131
   Grade I                            79    60 (75.9)            19 (24.1)           
   Grade II                           24    13 (54.2)            11 (45.8)           
   Grade III                          13    9 (69.2)             4 (30.8)            
  **Myometrial infiltration**         116   82 (70.7)            34 (29.3)           0.541
   \< 50%                             58    43 (74.1)            15 (25.9)           
   ≥ 50%                              58    39 (67.2)            19 (32.8)           
  **Invasive front of the tumor**                                                    
  **FIGO**                            106   71 (67.0)            35 (33.0)           0.004^\*\*^
   IA                                 53    42 (79.2)            11 (20.8)           
   IB                                 36    21 (58.3)            15 (41.7)           
   II                                 13    8 (61.5)             5 (38.5)            
   III                                4     0 (0.0)              4 (100.0)           
  **Grade**                           106   71 (67.0)            35 (33.0)           0.213
   Grade I                            72    52 (72.2)            20 (27.8)           
   Grade II                           22    13 (59.1)            9 (40.9)            
   Grade III                          12    6 (50.0)             6 (50.0)            
  **Myometrial infiltration**         106   71 (67.0)            35 (33.0)           0.014^\*^
   \< 50%                             55    43 (78.2)            12 (21.8)           
   ≥ 50%                              51    28 (54.9)            23 (45.1)           

^\*^Positive ≥ 65 ^†^Negative \< 65.

###### Multivariate logistic regression model related to the myometrial invasion ≥50% (N = 89)

  Variable                                                   OR      95% Interval confidence   P-value
  ---------------------------------------------------------- ------- ------------------------- -----------
  **Grade**                                                                                    
   Differentiated tumors (Grade I)                           1                                 
   Moderateley-poorly differentiated tumors (Grade II-III)   3.484   (1.284-9.524)             0.014^\*^
  **ALCAM**                                                                                    
   Positive                                                  1                                 
   Negative                                                  3.273   (1.200-8.932)             0.021^\*^
  **MMP-9**                                                                                    
   Positive                                                  1                                 
   Negative                                                  1.629   (0.602-4.409)             0.337
  **ETV5**                                                                                     
   Positive                                                  1                                 
   Negative                                                  0.556   (0.194-1.592)             0.274

ALCAM maintained a close and inverse relation with MMP-9 at the invasive front of the tumor (p=0.004; OR 0.26) (Table [3](#T3){ref-type="table"}). This relation was only preserved in poor prognosis tumors when the cohort was divided according to clinical parameters, i.e. either in tumors with moderately-poorly differentiated EEC histology (p=0.02; OR 0.08), in patients presenting \>50% of myometrial infiltration (p=0.016; OR 0.19), and in ETV5-positive tumors (p=0.009; OR 0.22). Altogether, our results demonstrated that ALCAM-negativity is a marker for myometrial invasion at the invasive front. Its close and inverse relation with MMP-9 in poor prognosis scenarios, led us speculate that ALCAM-negativity might be due to an increased shedding of the protein by the metalloproteinase at the invasive front of poor prognostic tumors.

###### ALCAM and MMP-9 correlation at the invasive front of the tumor

  Variable, No. (%)                              Σ    ALCAM Positive^\*^   ALCAM Negative^†^   P-value       OR (Positive/Negative)
  ---------------------------------------------- ---- -------------------- ------------------- ------------- ------------------------
  **All**                                        95   64 (67.4)            31 (32.6)           0.004^\*\*^   0.26 (0.10-0.66)
   MMP-9 Positive                                47   25 (53.2)            22 (46.8)                         
   MMP-9 Negative                                48   39 (81.3)            9 (18.8)                          
  **Clinical parameters**                                                                                    
  **Grade**                                                                                                  
  ** Differentiated tumors**                     64   46 (71.9)            18 (28.1)           0.162         N.S
   MMP-9 Positive                                26   16 (61.5)            10 (38.5)                         
   MMP-9 Negative                                38   30 (78.9)            8 (21.1)                          
  **Moderately- Poorly differentiated tumors**   31   18 (58.1)            13 (41.9)           0.020^\*^     0.08 (0.03-0.63)
   MMP-9 Positive                                21   9 (42.9)             12 (57.1)                         
   MMP-9 Negative                                10   9 (90.0)             1 (10.00)                         
  **Myometrial infiltration \<50%**              53   41 (77.4)            12 (22.6)           0.190         N.S
   MMP-9 Positive                                25   17 (68.0)            8 (32.0)                          
   MMP-9 Negative                                28   24 (85.7)            4 (14.3)                          
  **Myometrial infiltration ≥50%**               42   23 (54.8)            19 (45.2)           0.016^\*^     0.19 (0.03-0.65)
   MMP-9 Positive                                22   8 (36.4)             14 (63.6)                         
   MMP-9 Negative                                20   15 (75.0)            5 (25.0)                          
  **Molecular features**                                                                                     
  **ETV5 Positive**                              64   40 (62.5)            24 (37.5)           0.009^\*\*^   0.22 (0.07-0.69)
   MMP-9 Positive                                37   18 (48.6)            19 (51.4)                         
   MMP-9 Negative                                27   22 (81.5)            5 (18.5)                          
  **ETV5 Negative**                              25   19 (76.0)            6 (24.0)            1.000         N.S
   MMP-9 Positive                                7    5 (71.4)             2 (28.6)                          
   MMP-9 Negative                                18   14 (77.8)            4 (22.2)                          

^\*^Positive ≥ 65 ^†^Negative \< 65.

ALCAM shedding takes place in tumors with myometrial invasion and correlates with MMP-9 expression {#s2_3}
--------------------------------------------------------------------------------------------------

In order to evaluate the possible association between ALCAM shedding and myometrial invasion, we analyzed the expression of soluble ALCAM (sALCAM) by ELISA, in 40 uterine aspirates from moderately-poorly differentiated EEC patients with different depth of myometrial infiltration. The uterine aspirate is a bodyfluid that is collected from inside of the uterine cavity, and is mainly formed by the secretion of the tumor cells and other cells from the endometrium, enabling the detection of cleaved ALCAM produced by the tumor. We confirmed that sALCAM was significantly increased in patients presenting myometrial invasion \>50% (Figure [2A](#F2){ref-type="fig"}). Moreover, ROC analysis showed that sALCAM in uterine aspirates is a significant predictor of myometrial infiltration (AUC 0.8; p=0.001) (Figure [2B](#F2){ref-type="fig"}). In fact, when ALCAM is set at a cut-off of 9.375 ng/mg, the model presents a sensitivity of 87% and a specificity of 70.6%.

![Soluble ALCAM detected in uterine aspirates is a marker of myometrial invasion and correlates with MMP-9\
**(A)** Soluble ALCAM detected by ELISA in uterine aspirates was significantly increased in patients presenting myometrial invasion (p-value\<0.001). ALCAM values were normalized to total protein amount from the uterine aspirates. **(B)** ROC curve of sALCAM individual marker demonstrated its prognostic value to discriminate patients with myometrial invasion (AUC=0.800; p-value=0.001). **(C)** Two different examples of gelatin zymography from uterine aspirates and detection of the different forms of MMP-9 and MMP-2. **(D)** Principal component analysis from the MMP-9 detected molecular forms evidenced two principal components: C1 (75.18% of the variability) and C2 (13.86% of the variability). The factor loadings, correlation between the original variables and the C1 component, of each form can be observed in the graph. The KMO obtained was 0.80 and the t Barlett \<0.001. **(E)** The principal component C1 and the sALCAM were significantly correlated in all patients (R=0.447; p-value=0.004). **(F)** The correlation between the C1 component and sALCAM was significant in patients with myometrial invasion \>50% (R=0.575; p-value=0.004).](oncotarget-09-16648-g002){#F2}

Then, the relation between sALCAM and MMP-9 was assessed in uterine aspirates by performing a gelatin zymography of the same patients (Figure [2C](#F2){ref-type="fig"}). Linear regression analyses ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}) evidenced a significant positive correlation between sALCAM with all MMP-9 detected forms, with the exception of the more labile active form. No correlation was found with the MMP-2 forms (data not shown). In order to avoid the problems derived from the simultaneous use of several measurements that reflect expressions of molecular forms of the same enzyme ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}), PCA was addressed to explore the close relationship among the four MMP-9 forms and reduce their number before performing regression analysis. Two main components C1, which explains 75.18% of the variability of the original dataset, and C2 which only explains 13.86%, were extracted (Figure [2D](#F2){ref-type="fig"}). Regression analyses showed a strong and positive correlation between sALCAM and C1, and specifically in patients presenting myometrial invasion \>50% (R=0.575; p=0.004) (Figure [2E, 2F](#F2){ref-type="fig"}). These results suggested that at the invasive front of the tumor, ALCAM extracellular shedding by MMP-9 could be an important process in myometrial invasion.

ALCAM and MMP-9 are important actors at the invasive front of an *in vivo* model of EEC dissemination {#s2_4}
-----------------------------------------------------------------------------------------------------

The Hec1A-ETV5 overexpression model has been extensively used to mimic the process of tumor invasion in EEC \[[@R33]--[@R35]\], as ETV5 overexpression is known to induce EMT in EEC and has been reported at the invasive front of EEC tumors, promoting migration and invasion *in vitro* and *in vivo*. Furthermore, the parental Hec1A cell line is representative of moderately-poorly differentiated EEC tumor with epithelial-like morphology \[[@R33], [@R36]\]. To study ALCAM in a controlled environment, which represents a realistic approach towards the process of dissemination of EC, we generated orthotopic murine models with Hec1A (n=5) or its ETV5-overexpressing cells (n=4), directly injected into the uterus of the mice. In this model, tumor cells are localized in the same microenvironment of the original tumor, resembling the processes of tumor growth and myometrial infiltration under endometrial stimuli.

As expected, the tumors generated by the ETV5-overexpressing cells presented larger myometrial invasion and tumor burden ([Supplementary Figure 1A-1B](#SD1){ref-type="supplementary-material"}). While in the ETV5-overexpressing tumors, we observed disseminated cells in finger-like strands or single-cells, projecting into the stroma at the invasive front; in the Hec1A tumors, cells invaded forming clusters (see arrows in Figure [3A](#F3){ref-type="fig"}), as previously observed by Muinelo-Romay et al. *in vitro* \[[@R37]\]. The immunohistochemical staining of uncleaved ALCAM, MMP-9, and ETV5 in the mice\'s primary tumors unveiled that ALCAM expression is reduced at the invasive front of ETV5-overexpressing compared to Hec1A tumors (p\<0.05; Figure [3B](#F3){ref-type="fig"}), and moreover, the pattern of expression is modified from a very membranous staining in Hec1A tumors to a diffuse cytoplasmic staining in ETV5-overexpressing cells (Figure [3A](#F3){ref-type="fig"}).

![ALCAM is decreased at the invasive front of primary tumors of a controlled model of EEC dissemination\
**(A)** Upper: Immunohistochemistry of ETV5, ALCAM and MMP-9 in Hec1A control mice. ALCAM and MMP-9 presented a homogeneous staining between the superficial and invasive front or disseminated cells. Black arrow signals a cluster of disseminated cells released from the primary tumor. Down: Immunohistochemistry of ETV5, ALCAM and MMP-9 in Hec1A-ETV5 mice. ALCAM expression was decreased at the invasive front of the tumor, concomitant with an increase of MMP-9 expression. Black arrows evidenced disseminated cells in finger-strand or individual cells, released from the ETV5-overexpressed primary tumor. **(B)** Representation of the intensity of staining of ALCAM and MMP-9. Only, ALCAM expression was significantly decreased at the invasive front of the ETV5-overexpressing mice, compared to control (^\*^p\<0.05). **(C)** Relative intensity of ALCAM and MMP-9 markers at the invasive front compared to the superficial tumor. While in the control mice, both markers where homogeneous across the section, in the ETV5-overexpressing mice we observed a decreased in ALCAM expression concomitant with an increase in MMP-9 expression in the invasive front of the primary tumors.](oncotarget-09-16648-g003){#F3}

Interestingly, the intensity of ALCAM and MMP-9 showed no variation between the superficial or the invasive area in Hec1A tumors, but their intensity was altered in the ETV5-overexpressing tumors. In those, MMP-9 increased concomitant with a decrease in ALCAM from the superficial area to the invasive front of the tumor (Figure [3](#F3){ref-type="fig"}, [Supplementary Figure 1C](#SD1){ref-type="supplementary-material"}).

As a result of the *in vivo* model, we evidenced that the cell-cell contacts of the Hec1A invading cells seem to be preserved, as shown by the highly collective migration and a homogeneous ALCAM expression. However, the ETV5-overexpressing invading cells were more prone to present switching between thin cords and single-cells, both related to decreased or more transient contacts and higher rate of cleaved ALCAM expression. We finally confirmed that in an invasive scenario, ALCAM and MMP-9 are important actors at the invasive front of the tumor.

Recovery of ALCAM expression reduced the aggressiveness of invasive EEC cells {#s2_5}
-----------------------------------------------------------------------------

To understand the role of ALCAM at the invasive process, we recovered its expression in the invasive Hec1A-ETV5 model by using two ALCAM-overexpression vectors: one containing a full-length ALCAM (full-ALCAM) and another containing the extracellular and transmembrane regions (ALCAMcytoless), both cloned in pmCherry-N1 vectors (Figure [4A](#F4){ref-type="fig"}). When transiently transfected in Hec1A-ETV5 cells, ALCAM-overexpression was localized predominantly in the plasma membrane (Figure [4B-4C](#F4){ref-type="fig"}). To evaluate the effects of ALCAM-recovery in ETV5-overexpressing cells, we used 3D *in vitro* approaches that closely mimic the *in vivo* settings. We used a spheroid model to quantitatively study the spreading of cell aggregates on fibronectin-coated stripes. In addition to reproduce characteristics of the *in vivo* environment, this model allows us to analyze the competition between cell--cell and cell--substratum adhesion on tissue spreading \[[@R38]\]. In both conditions (ALCAM full-length and ALCAMcytoless) the speed was significantly decreased compared to the control cells (Figure [4D-4E](#F4){ref-type="fig"}). However, the larger difference was found in the full-length ALCAM-transfected cells. In fact, we observed that the mean time of disaggregation of the Cherry-control spheroids was around 5 h, while ALCAM full-length and ALCAMcytoless expressing aggregates needed approximately 21 h and 18 h, respectively (Figure [4D](#F4){ref-type="fig"}). Moreover, the pattern of spreading in control cells presented a more spindle-shaped phenotype, with larger presence of individual cells and protrusions, highly dynamic transient cell-cell contacts, migration in a sheet fashion and presentation of chemotactic abilities. In contrast, full-ALCAM and ALCAMcytoless cells presented an increased intercellular adhesion phenotype and a more collective pattern of spreading (Figure [4D](#F4){ref-type="fig"}, [Supplementary Videos 1](#SD2){ref-type="supplementary-material"}-[3](#SD4){ref-type="supplementary-material"}). Consequently, ALCAM recovery clearly impaired the migratory abilities of ETV5-overexpressing cells.

![ALCAM overexpression in mesenchymal Hec1A-ETV5 cells decreased cell migration and enhanced cell-cell adhesion\
**(A)** Representation of the two vectors constructed to overexpress ALCAM: full-length ALCAM and ALCAMcytoless inserted in the pmCherry-N1 construct. **(B)** Images of the Hec1A-ETV5 cell line transfected with the pmCherry vector as a control, and both ALCAM-overexpression constructs. **(C)** Western-blot analysis evidenced that ALCAM-Cherry was predominantly expressed in the cell membrane in Hec1A-ETV5 cells. **(D)** Images of the 3D spheroid-spreading model are illustrated at different time points. In the control cells, the spheroids were almost disaggregated after 5 h, whilst the mean time for disaggregation for the ALCAMcytoless cells was around 18 h, and more than 21 h for the full-length ALCAM cells. **(E)** Effect of ALCAM overexpression on migration was assessed by a 3D spheroid-spreading model on 200 μm fibronectin-coated stripes. On the left, box plot of the speed of migration for each cell line. On the right, representative images at time 0 h and at 24 h are illustrated and the spreading reached at 24 h is outlined in the images. Migration decreased in cells transfected with full-length ALCAM (^\*\*^p\<0.01) and ALCAMcytoless (^\*^p\<0.05) compared to control (m/s, meter/second) **(F)** Left: Two Cherry transiently transfected cells were put into contact and allowed to form adhesion. After 4 and 10 min, we applied an increasing measurable force (nN) up to the disruption of the formed cell doublet. Right: Full-length ALCAM-overexpression increased cell-cell adhesion at all points, as shown by quantification of the separation force (^\*\*\*^p\<0.001). However, ALCAMcytoless only increased cell-cell adhesion at 4 min and showed no differences with control line at 10 min. **(G)** Western-blot analysis of ALCAM-overexpression in Hec1A-ETV5 cells demonstrated a significant decrease in the levels of ERK-phosphorylation.](oncotarget-09-16648-g004){#F4}

To verify these effects we evaluated how ALCAM-rescue affects the formation and strength of cell-cell adhesion. We used two micropipettes to put into contact two isolated cells maintained in suspension, to avoid cell-matrix interactions, and initiate adhesion. Single cells were chosen under a fluorescence microscope to verify the Cherry-transfection. The mean separation force (SF) is used as a read-out of the strength of adhesion for a precise contact time. In all the cases, the SF required to disrupt the cell doublet increased with the contact time. We observed that at 4 min both ALCAM-transfected cells presented significantly larger adhesion than the control line (Figure [4F](#F4){ref-type="fig"}). Cells expressing full-length ALCAM displayed stronger intercellular adhesion, as shown by the two-fold increase in their SF compared to control cells, and were more adhesive than cells expressing ALCAMcytoless. In contrast, at 10 min only the full-length ALCAM-transfected cells presented significantly stronger adhesion than the control. Thus, we showed that ALCAM shedding was important to reduce the adhesive properties of the cells. In this particular context, the cytoplasmic tail plays an important role in cell-cell adhesion formation or maturation.

The molecular pathway by which ETV5 promotes its invasive functions in EC has been recently postulated by Alonso-Alconada et al. \[[@R39]\]. The authors described how ETV5 works through the BDNF--TrkB--ERK1/2 axis by inducing ERK1/2 phosphorylation, leading to the promotion of migration and invasion. In this work, we observed that ALCAM-overexpression was concomitant with a decrease in p-ERK, without reverting to an epithelial phenotype (Figure [4G](#F4){ref-type="fig"}), but impairing the migratory and increasing the adhesive properties promoted by ETV5. Although overexpression of the ALCAMcytoless is sufficient to reduce the levels of p-ERK and to decrease spheroid spreading, ALCAM full-length is necessary to increase cell-cell adhesion with time.

DISCUSSION {#s3}
==========

The principal components of adherens junctions in epithelial cells are E-cadherin and β-catenin. E-cadherin is a calcium-dependent transmembrane receptor that interacts homotypically to the E-cadherin of adjacent cells and heterotypically to cytoplasmic-binding proteins, including β-catenin, to transduce external signals within the cell and provide a physical link to the cytoskeleton \[[@R40]\]. Loss of epithelial polarity and decreased E-cadherin lead to EMT, they have been described to promote invasion and are related to poor prognosis and high-grade EC tumors \[[@R41]\]. In addition, the upregulation of the ETV5 Ets transcription factor has been linked to EMT and associated with myometrial infiltration in EC \[[@R42]\]. Our previous *in vitro* and *in vivo* studies evidenced that ETV5 promotes EMT by modulation of ZEB1 expression and consequent E-cadherin repression, leading to a complete reorganization of cell-cell and cell-substrate contacts and in the acquisition of migratory and invasive capabilities \[[@R33], [@R34]\]. Moreover, ETV5 has been shown to co-localize with MMP-2 and -9 at the invasive front of the tumor \[[@R42]\]. The high expression of both metalloproteinase and COX-2, another direct target of ETV5, has been correlated to poor prognosis and relapse in EC \[[@R43], [@R44]\].

A critical role has been evidenced in the process of EMT and E-cadherin expression downregulation, by SNAIL-related zinc-finger transcription factors (SNAIL and SLUG). The overexpression of SNAIL and SLUG has been seen closely associated with the reduced expression of E-cadherin in EC, and particularly at the invasive front of the tumor \[[@R45], [@R46]\]. Specifically, SNAIL nuclear immunoexpression has been described to take place concomitantly with a decrease in E-cadherin expression at the invasive front of stage IB EEC \[[@R45]\].

In this study, we used an extracellular-ALCAM antibody to assess the non-cleaved protein expression by immunohistochemistry in two different tumor areas from 116 EEC primary tumors, i.e. at the superficial and the invasive front. Then, its expression was related to a set of epithelial (E-cadherin, β-catenin) and mesenchymal (ETV5, COX-2, MMP-2, MMP-9, SNAIL, and SLUG) EEC relevant markers. While at the superficial tumor, uncleaved ALCAM maintained a correlation with the major adhesion complex E-Cadherin/β-catenin; at the invasive tumor, where a more mesenchymal microenvironment takes place, it correlated with COX-2, SNAIL, MMP-9 and ETV5 mesenchymal markers. Interestingly, in the moderately-poorly differentiated tumors E-cadherin and ALCAM were positively correlated at the superficial area, whilst ETV5 and MMP-9 presented a significant negative correlation with extracellular ALCAM at the invasive front. Moreover, we evidenced that the correlation between ALCAM and MMP-9 was only significant in poor prognostic scenarios, i.e. in moderately-poorly differentiated tumors, in patients presenting myometrial invasion \>50%, and ETV5-positive tumors. Furthermore, at the invasive front, we demonstrated that ALCAM-negativity was an independent prognostic marker of myometrial invasion together with the tumor grade.

ALCAM-negativity was directly associated to an increased shedding of the protein, as demonstrated by the increased expression of sALCAM in uterine aspirates from patients with moderately-poorly differentiated EEC presenting myometrial invasion \>50%. In our study, ROC analysis corroborated sALCAM as a significant predictor of myometrial invasion (AUC=0.80). These findings are particularly interesting as uterine aspirates are the preferable biopsy used in EC diagnosis and the assessment of sALCAM might open the avenue to develop a potential tool to determine pre-operatively the myometrial infiltration (sensitivity 87.0%, specificity 70.6%) at the time of diagnosis, even in earlier EC stages \[[@R47]\]. In addition, sALCAM and MMP-9 were significantly strongly correlated in the same patients presenting myometrial invasion \>50%. Actually, sALCAM has been detected in FFPE \[[@R22]\] and in several biofluids \[[@R31], [@R48], [@R49]\], and related to tumor progression and poor patient outcome. Disruption of ALCAM--ALCAM interactions between cells promotes tumor cell motility and metastasis, then shedding may predict tumor progression at a molecular level. In fact, ectopic expression of mutant ΔN-ALCAM in melanoma cells induced loss of cellular aggregation, increased motility in skin reconstructs and lung metastasis formation at the expense of primary tumor \[[@R50]\].

*In vivo* and *in vitro* ETV5-overexpressing models of EEC were selected. Only in the ETV5-overexpressing invading tumors, uncleaved ALCAM was decreased at the invasive front, concomitant with an increase in MMP-9 expression. MMP-9 expression has been associated with increased metastatic potential in many cancer types \[[@R51]\]. Its activity modulates cell-cell and cell-matrix attachment and has been described to regulate the cell invasion and migration processes. Here, we could hypothesize that MMP-9 is responsible of ALCAM shedding, in invasive scenarios.

Moreover, we proved that ALCAM-recovery in ETV5-overexpressing cells decreased migration, increased cell-cell adhesion, and presented a more collective pattern of spreading. In addition, we evidenced that a larger adhesion force was necessary to separate the full-length ALCAM-transfected cell doublet, indicating its capacity to promote intercellular adhesion strengthening and manifesting the crucial role of its cytoplasmic tail in the maturations of cell-cell adhesion. In fact, the cytoplasmic tail of ALCAM has been described to interact with the actin cytoskeleton, and could be essential in translation of external mechanical forces into the cell to activate biochemical signals \[[@R50], [@R52]\].

These differences in cell-cell adhesion, in the cell speed and the pattern of migration could be partially explained by the decrease of the active levels of p-ERK. The link between the role of BDNF in the modulation of EMT induced by ETV5 and the acquisition of cell migratory/invasive capabilities through p-ERK phosphorylation has been established \[[@R39]\]. The known role of the BDNF--TrkB--ERK1/2 axis on neuronal plasticity and organogenesis might be mediating pro-metastatic events in endometrial cancer and as consequence the decrease in the p-ERK levels would lead to a less aggressive phenotype \[[@R39]\]. Moreover, some authors evidenced that sustained MAPK activation could lead to enhanced induction of proteolytic enzymes in the surrounding environment in tumors and specifically, the inhibition of ERK activation by MEK inhibitor PD098059 has been described to partially block MMP-9 production and attenuate the *in vivo* invasiveness of head and neck squamous cancer cells \[[@R53]\].

Although further research is needed to define the exact mechanisms, *in vitro* and *in vivo* models evidenced that ALCAM participates in cell-cell adhesion and collective cell migration, and suggested that to allow invasion in the frontier between tissues-restricted carcinoma and disseminated tumor cells, a dynamic and adaptive switch between ALCAM expression at the cell surface and cleaved ALCAM by MMP-9 might take place. In fact, cancer cell invasion is currently viewed as a heterogeneous and adaptive process \[[@R54]\] in which, the plasticity in cell adhesion, the dynamics of the cytoskeleton and the mechanotransduction of external stimuli are key processes. Taking into account that myometrial invasion is highly associated with poor prognosis and to a limited therapeutic response, our research opens an avenue for the use of ALCAM-recovery as a therapeutic approach to control tumor invasion.

MATERIALS AND METHODS {#s4}
=====================

Human endometrial cancer samples {#s4_1}
--------------------------------

Formalin-fixed paraffin-embedded tissue samples from 116 EEC patients were recruited from the Hospital del Mar (Barcelona, Spain). For each patient, we selected 4 macroscopically differentiated areas: 2 superficial, which were obtained from the core of tumor; and 2 invasive, which were obtained from the tumor in contact with the invasive front.

Forty uterine aspirates, from EEC patients were collected prior to surgery by aspiration in the Vall Hebron University Hospital (Barcelona, Spain), with a Cornier Pipelle (Eurogine Ref. 03040200). PBS1x was added (1:1) and centrifuged 20 min at 2,500 rcf to separate the soluble fraction.

All samples were obtained after the approval of the ethical committee of each institution. The clinicopathologic characteristics of all patients are detailed in [Supplementary Table 4](#SD1){ref-type="supplementary-material"}.

Immunohistochemical staining {#s4_2}
----------------------------

Tissue microarray and immunohistochemistry were performed as previously described \[[@R34]\]. ALCAM, E-cadherin, β-catenin, ETV5, COX-2, MMP-2, MMP-9, SLUG, and SNAIL immunohistochemical expressions were analyzed in both areas of the tumor (superficial and invasive). Immunohistochemical staining for ALCAM was conducted with MOG/07 antibody (ab49496; Abcam, Cambridge, MA, USA) directed against the extracellular domain of the protein. Specifically, the antibody is raised against a 200-amino-acid-long peptide from the extracellular region of ALCAM, detecting the full-ALCAM or non-cleaved protein. Antigen retrieval and primary antibody incubation were performed as previously described \[[@R32]\]. To detect MMP-2, MMP-9, and ETV5, citrate buffer pH 9 was used for antigen retrieval. Then the sections were incubated with 1:100 rAb ETV5 (H-100; Santa Cruz Biotechnology, CA, USA), 1:50 mAb MMP-2 (CA-4001; Abcam, Cambridge, MA, USA), and 1:50 rAb MMP-9 (3852; Cell Signaling Technology, Beverly, MA, USA) for 1h or 2h (ETV5) at room temperature. Detection of COX-2, SLUG, and SNAIL was performed with antigen retrieval citrate pH 6 buffer. The sections were incubated overnight using 1:100 gAb COX-2 (M-19; Santa Cruz Biotechnology, CA, USA), 1:250 rAb SLUG (ab27568; Abcam), 1:125 gAb SNAIL (ab53519; Abcam) for 1h at room temperature. Primary antibodies mAb E-cadherin and mAb β-Catenin (36 and 14; Roche, Basel, Switzerland) were used with Ventana Benchmark automated slide stainer, 24 min at 36°C.

A pathologist evaluated the expression of each protein using immunoreactive scores (IRS). ALCAM, E-Cadherin, SNAIL, SLUG, and COX-2 expressions were evaluated from the product of the staining intensity (ranging from 1-3) and the percentage \[0-100%\] of neoplastic cells with positive staining. The product of the two assessments yielded final values on a scale ranging from \[0--300\]. ETV5, β-catenin, MMP-2 and MMP-9 were only evaluated based on the percentage, in scale IRS \[0-100%\]. For the selected candidates (ALCAM, ETV5 and MMP-9), the IRS was dichotomized (positive/negative), by using the average of their staining (obtained from the superficial and the invasive staining) and the cut-off values were established with the first quartile of its distribution, in each case. The cut-off for each protein was: ALCAM positive ≥ 65, ETV5 positive ≥ 25, MMP-9 positive \>5.

Soluble ALCAM detection in uterine aspirates {#s4_3}
--------------------------------------------

The ALCAM Duoset ELISA kit (R&D Systems, Minneapolis, USA) was used to detect ALCAM levels in the supernatant of the uterine aspirates according to manufacturers\' instructions. All samples were diluted 1:100 in BSA 1%.

Zymography {#s4_4}
----------

Proteins with metalloproteinase activity were identified by gelatin zymography and equal quantities of protein, from the uterine aspirates, were size fractionated as previously described \[[@R35]\].

Cell lines, constructs and transient cell lines generation {#s4_5}
----------------------------------------------------------

The human Hec1A and the Hec1A-ETV5 EEC cells were generated and maintained as described in Monge et al. \[[@R35]\]. To monitor non-invasively tumor grafts of Hec1A and Hec1A-ETV5 cell lines, cells were infected with lentiviruses bearing pLenti CMV V5-LUC Blast (w567-1) (Addgene, Cambridge, MA, USA) to constitutively express the luciferase reporter gene, as previously described \[[@R55]\]. For transient ALCAM-overexpression in Hec1A-ETV5, we amplified ALCAM full-length and ALCAM extracellular-transmembrane domains, without the cytoplasmic tail (ALCAMcytoless), from an EEC tissue, using the forward primer 5′-GCAACTCGAGATGGAATCCAAGGGGGCCA-3′, and 2 reverse primers 5′-GCTTGAATTCCGGCTTCAGTTTTGTGATTGTT-3′ and 5′- GCTTGAATTCGCAGCCAGTAGACGACACCAG-3′, respectively. Both amplified regions were inserted in pmCherry-N1 vector (Clontech Laboratories, Mountain View, CA, USA) with *XhoI* and *EcorI*. Transfection was performed using Lipofectamine 2000 (Invitrogen) following manufacturers\' instructions.

Orthotopic murine model and bioluminescent imaging {#s4_6}
--------------------------------------------------

All the procedures were performed according to the guidelines of the Spanish Council for Animal Care and the institutional guidelines for animal welfare (CEEA 23/16). A total of 9 six-week-old female athymic nude mice (Charles River Laboratories, Inc, Wilmington, MA) were inoculated by transmyometrial injection of Hec1A luciferase control cells (n=5) and stably transfected Hec1A-ETV5 luciferase cells (n=4) as described in \[[@R56]\]. Mice were sacrificed 3 weeks after the injection. All extracted tissues were formalin-fixed, stained with haematoxylin and eosin, and evaluated by a pathologist. After cells injection and before sacrifice, a weekly follow-up was carried out using the IVIS system (Xenogen Corporation) coupled to Living Imaging software 4.2 (Xenogen Corporation) in order to detect tumor growth by bioluminescent imaging. Luciferin (Firefly Luciferin, Caliper Lifescience Corp, Hopkinton, MA, USA) was used as the substrate for the luciferase expressing tumor cells and injected intraperitoneally at a concentration of 150 mg/kg in PBS.

Western-blot and protein cell extraction {#s4_7}
----------------------------------------

Cell extraction and western-blot were performed as previously described \[[@R33]\]. Incubation with primary antibodies was performed at 4°C overnight using 1:500 mAb ALCAM (MOG/07, Abcam, Cambridge, MA, USA); 1:2000 rAb a-Tubulin, 1:2000 rAb ERK1/2, 1:1000 rAb p-ERK1/2 (Cell Signaling Technology, Beverly, MA, USA), 1:2500 rAb Lamin (Santa Cruz, CA, USA), 1:5000 rAb mCherry (\[[@R57]\]; an aliquot of the antibody was kindly provided by Drs. Anna Santamaría and Erich A. Nigg). Nuclear, membrane and cytosolic fractionation of transfected Hec1A-ETV5 cells was performed by using a Subcellular Fractionation Kit (Pierce) as per the manufacturer\'s instructions.

Measurement of the separation force between cells {#s4_8}
-------------------------------------------------

Forces were measured on the stage of an inverted epifluorescence microscope (Leica) equipped with objectives of 63x (PL FLUOTAR; NA/0.7; C PLAN NA/0.75) and with a cooled CCD C5985 (Hamamatsu) or Coolpix 5000 camera (Nikon) as previously described \[[@R58]\]. To preserve intact the cell surface proteins, cells were dissociated with Cell dissociation enzyme-free buffer (Gibco, NY, USA) and then transferred in working medium (CO2-independent medium, Invitrogen, CA, USA) and used immediately. Two isolated cells were put into contact and allow forming adhesion for specific period times. Aspiration was monitored continuously by a pressure sensor (model DP103-38; Validyne) during the separation process and the values recorded for each of the last two cycles in the series (*P*n-1 and *P*n) were used to calculate the separation force (SF) for each doublet using the equation: SF = *π* (*d*/2)2 (*P*n-1+*P*n)/2 where *d* is the inside diameter of the left pipette. Results for 15--30 measurements were used to obtain the mean SF for a specific contact time.

Aggregate spreading {#s4_9}
-------------------

Aggregates were obtained from 5 mL of cell suspension in CO2-equilibrated culture medium at a concentration of 4 × 10^5^ cells per milliliters in 25 mL Erlenmeyer flasks and placed in a gyratory orbital shaker at 75 rpm at 37°C for 22 h. The flasks were pretreated with 2% dimethylchlorosilane in chloroform to prevent adhesion of cells to the glass surface.

For the preparation of coated glass substrates: twenty-five millimeter circular glass coverslips were sonicated in ethanol for 5 min, dried at ambient temperature, and exposed to deep UV for 5 min. Fibronectin (Sigma-Aldrich, Missouri, USA) coating was performed using a 0.1 mg/mL solution of fibronectin in PBS solution (pH 7.4) for 1 h. Mixed coating of fibronectin and PEG-PLL (PLL(20)-g\[3.5\]-PEG(2), Surface Solution) was done by mixing at various rates a 0.1 mg/mL fibronectin in phosphate buffer solution (PBS; pH 7.4) and a 0.1 mg/mL PEG-PLL in Hepes solution (pH 7.3) for 1 h. Coverslips were then rinsed with PBS (pH 7.4).

As previously described \[[@R59]\], aggregates were deposited randomly on striped fibronectin-coated coverslips in a magnetic imaging chamber (Chamlide CMB, CM-B25-1) filled with CO2-equilibrated culture medium. Spreading was observed using a NIKON confocal microscope with an x10 air objective and a 37°C heating cube system. Bright field images were recorded for 36 h with a CCD camera (Luca-R, Andor) using NIS-Elements software. The increased spreading was measured at different time points with Image J software (National Institutes of Health, Bethesda), which allowed calculating the speed of migration for each cell line.

Immunofluorescence {#s4_10}
------------------

After 48 h of transfection, cells seeded onto glass coverslips were fixed with 4% paraformaldehyde, blocked in PBS-BSA 4% and incubated with DAPI for 15 min at RT in dark. Coverslips were mounted using the Aqua/Poly Mount medium (Polysciences Europe GmbH, Eppelheim, Germany). Fluorescence images were captured with Spectral Confocal Microscope FV1000 (Olympus, Hamburg, Germany).

Statistical analysis {#s4_11}
--------------------

For continuous variables: univariate and multivariate linear regression analyses were performed to evaluate the association between ALCAM and epithelial or mesenchymal markers at the superficial and the invasive front. For each cohort, a stepwise method was used to select the explanatory variables based on analysis of variance, checking the normality (Kolmogorov-Smirnov) and the independence of residuals (Durbin-Watson).

Receiver operating characteristic (ROC) curve analysis was conducted on the individual soluble ALCAM (sALCAM) expression detected in uterine aspirates at diagnosis, to evaluate the potential of this parameter as a marker to discriminate patients presenting myometrial infiltration. To explore its relationship with the different forms of MMP-9 present in the uterine aspirates, we performed a factor analysis with extraction of principal component (PCA) and then, a regression analyses with sALCAM levels. The normal distribution of the data was verified (Kolmogorov-Smirnov) and levels were ln-transformed for linear analyses. Non-parametric test (Mann Whitney) were used for comparisons of data sets whose distributions deviate from normal. Measurements were made in triplicates in three independent experiments and presented with the Mean±SD (except for the separation force experiments, which were presented by Mean±SEM).

For categorical variables: the relationships between ALCAM expression at the superficial and the invasive front and clinicopathological parameters were tested in univariate analysis by Chisquare and Fisher\'s exact test. Stratified analysis was performed to study the molecular features ALCAM/MMP-9/ETV5 and the crosstalk between ALCAM/MMP-9 and clinicopathological parameters. The odds ratios (OR), with their confidence interval (IC 95%) were obtained through bootstrapping methods. Logistic regression multivariate analysis was done for the clinicopathological parameters and the biomarkers status to determine independent predictors for myometrial infiltration.

All statistical analyses were performed using the IBM SPSS Statistics 21. All two-sided p-values \< 0.05 were considered statistically significant.
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